Detection of phosphorylated insulin receptor in colorectal adenoma and adenocarcinoma: Implications for prognosis and clinical outcome

Journal of Cellular Physiology

Volumn 230, Issue 3, 2015, Pages 562-567

  Abbruzzese, Claudia ^a   Diodoro, Maria Grazia ^a   Sperduti, Isabella ^a   Mileo, Anna Maria ^a   Pattaro, Giada ^a   De Salvo, Laura ^a   Cosimelli, Maurizio ^a   Perrotti, Nicola ^b   Paggi, Marco G ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN RECEPTOR;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; DISEASE FREE SURVIVAL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; ADENOMATOUS POLYPOSIS COLI; ADULT; CANCER GRADING; CELL TRANSFORMATION; GENETICS; HCT116 CELL LINE; ISOLATION AND PURIFICATION; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; TREATMENT OUTCOME;

ADENOMATOUS POLYPOSIS COLI; ADULT; CELL TRANSFORMATION, NEOPLASTIC; DISEASE-FREE SURVIVAL; HCT116 CELLS; HUMANS; NEOPLASM GRADING; PHOSPHORYLATION; PROGNOSIS; RECEPTOR, INSULIN; TREATMENT OUTCOME;

EID: 84920896851     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24733     Document Type: Article

References (30)

1. Bardou M, Barkun AN, Martel M. 2013. Obesity and colorectal cancer. Gut 62:933-947.
2. Berster JM, Goke B. 2008. Type 2 diabetes mellitus as risk factor for colorectal cancer. Arch Physiol Biochem 114:84-98.
3. Brierley GV, Macaulay SL, Forbes BE, Wallace JC, Cosgrove LJ, Macaulay VM. 2010. Silencing of the insulin receptor isoform A favors formation of type 1 insulin-like growth factor receptor (IGF-IR) homodimers and enhances ligand-induced IGF-IR activation and viability of human colon carcinoma cells. Endocrinology 151:1418-1427.
4. Chiefari E, Nevolo MT, Arcidiacono B, Maurizio E, Nocera A, Iiritano S, Sgarra R, Possidente K, Palmieri C, Paonessa F, Brunetti G, Manfioletti G, Foti D, Brunetti A. 2012. HMGA1 is a novel downstream nuclear target of the insulin receptor signaling pathway. Sci Rep 2:251.
5. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van BM, Goede SL, Ries LA. 2010. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116:544-573.
6. Fearon ER, Vogelstein B. 1990. A genetic model for colorectal tumorigenesis. Cell 61:759-767.
7. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, Vigneri R. 1999. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19:3278-3288.
8. Frederick MJ, VanMeter AJ, Gadhikar MA, Henderson YC, Yao H, Pickering CC, Williams MD, El-Naggar AK, Sandulache V, Tarco E, Myers JN, Clayman GL, Liotta LA, Petricoin EF, III, Calvert VS, Fodale V, Wang J, Weber RS. 2011. Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol 178:548-571.
9. Giovannucci E. 1995. Insulin and colon cancer. Cancer Causes Control 6:164-179.
10. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ, Lang NP. 2007. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 25:1476-1481.
11. Kinzler KW, Vogelstein B. 1996. Lessons from hereditary colorectal cancer. Cell 87:159-170.
12. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M, Dunn SE. 2008. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68:10238-10246.
13. Li Q, Li M, Wang YL, Fauzee NJ, Yang Y, Pan J, Yang L, Lazar A. 2012. RNA interference of PARG could inhibit the metastatic potency of colon carcinoma cells via PI3-kinase/Akt pathway. Cell Physiol Biochem 29:361-372.
14. Mattarocci S, Abbruzzese C, Mileo AM, Visca P, Antoniani B, Alessandrini G, Facciolo F, Felsani A, Radulescu RT, Paggi MG. 2009. Intracellular presence of insulin and its phosphorylated receptor in non-small cell lung cancer. J Cell Physiol 221:766-770.
15. Nagata N, Sakamoto K, Arai T, Niikura R, Shimbo T, Shinozaki M, Aoki T, Kishida Y, Sekine K, Tanaka S, Okubo H, Watanabe K, Sakurai T, Yokoi C, Akiyama J, Yanase M, Noda M, Itoh T, Mizokami M, Uemura N. 2014. Visceral abdominal fat measured by computed tomography is associated with an increased risk of colorectal adenoma. Int J Cancer.
16. Podlecki DA, Smith RM, Kao M, Tsai P, Huecksteadt T, Brandenburg D, Lasher RS, Jarett L, Olefsky JM. 1987. Nuclear translocation of the insulin receptor. A possible mediator of insulin's long term effects. J BiolChem 262:3362-3368.
17. Pollak M. 2008. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915-928.
18. Pollak M. 2012a. The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer 12:159-169.
19. Pollak MN. 2012b. Investigating metformin for cancer prevention and treatment: The end of the beginning. Cancer Discov 2:778-790.
20. Rosenzweig SA, Atreya HS. 2010. Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol 80:1115-1124.
21. Sandhu MS, Dunger DB, Giovannucci EL. 2002. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 94:972-980.
22. Sarfstein R, Werner H. 2013. Minireview: Nuclear insulin and insulin-like growth factor-1 receptors: A novel paradigm in signal transduction. Endocrinology 154:1672-1679.
23. Sciacca L, Vigneri R, Tumminia A, Frasca F, Squatrito S, Frittitta L, Vigneri P. 2013. Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. Nutr Metab Cardiovasc Dis 23:808-815.
24. Siegel R, Ma J, Zou Z, Jemal A. 2014. Cancer statistics, 2014. CA Cancer J Clin 64:9-29.
25. Signore M, Pelacchi F, Di MS, Runci D, Biffoni M, Giannetti S, Morgante L, De MM, Petricoin EF, Stancato L, Larocca LM, De MR, Pallini R, Ricci-Vitiani L. 2014. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. Cell Death Dis 5:e1223.
26. Towhid ST, Liu GL, Ackermann TF, Beier N, Scholz W, Fuchss T, Toulany M, Rodemann HP, Lang F. 2013. Inhibition of colonic tumor growth by the selective SGK inhibitor EMD638683. Cell Physiol Biochem 32:838-848.
27. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien, Makhson CR, D'Haens A, Pinter G, Lim T, Bodoky R, Roh G, Folprecht JK, Ruff G, Stroh P, Tejpar C, Schlichting S, Nippgen M, Rougier J. 2009. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417.
28. VanMeter A, Signore M, Pierobon M, Espina V, Liotta LA, Petricoin EF, III. 2007. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Rev Mol Diagn 7:625-633.
29. Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS. 2009. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 27:176-185.
30. Wong P, Weiner MG, Hwang WT, Yang YX. 2012. Insulin therapy and colorectal adenomas in patients with diabetes mellitus. Cancer Epidemiol Biomarkers Prev 21:1833-1840.